Methylation profiling

Dataset Information

0

Genetic and pharmacological targeting of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis


ABSTRACT: Metabolic dysfunction-associated steatohepatitis (MASH) is on the rise, and with limited pharmacological therapy available, identification of new metabolic targets is urgently needed. Oxalate is a terminal metabolite produced from glyoxylate by lactate dehydrogenase (LDHA). The liver-specific alanine-glyoxylate aminotransferase (AGXT) detoxifies glyoxylate, preventing oxalate accumulation. We report that AGXT is suppressed and LDHA is activated in livers from patients and mice with MASH, leading to oxalate overproduction. In turn, oxalate promotes steatosis in hepatocytes by inhibiting peroxisome proliferator activated receptor-alpha (PPARα) transcription and fatty acid β-oxidation (FAO), and induces monocyte chemotaxis via C-C motif chemokine ligand 2. In male mice with diet-induced MASH, blocking oxalate overproduction through hepatocyte-specific AGXT overexpression or pharmacological inhibition of LDHA potently lower steatosis, inflammation, and fibrosis by inducing PPARα-driven FAO, and suppressing monocyte chemotaxis, nuclear factor-kappaB and transforming growth factor-beta targets. These findings highlight hepatic oxalate overproduction as a new target for the treatment of MASH.

ORGANISM(S): Mus musculus

PROVIDER: GSE265985 | GEO | 2024/08/07

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-04-21 | MSV000094587 | MassIVE
2024-06-22 | PXD048073 | Pride
2024-08-05 | GSE261829 | GEO
2024-03-20 | GSE208632 | GEO
2016-07-01 | GSE81889 | GEO
2024-09-22 | GSE275576 | GEO
2024-09-22 | GSE275575 | GEO
2024-11-13 | GSE244832 | GEO
2021-08-27 | GSE159219 | GEO
2014-04-24 | GSE51712 | GEO